---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-086136"
form_type: "8-K"
ticker: "SXTP"
cik: "0001946563"
company_name: "60 DEGREES PHARMACEUTICALS, INC."
filed_at: "2026-08-06T20:07:36+00:00"
generated_at: "2026-08-06T20:09:58.097435+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# 60 Degrees Pharmaceuticals shareholders approve reverse stock split, equity plan amendment, and management success fee

## Summary
- Reverse stock split approved at ratio of 1:5 to 1:10, as determined by board.
- Equity plan amended to increase shares available by 800,000.
- Success fee approved: 5% of deal proceeds between $40M-$100M, 6% above $100M, for change of control or sale of Arakoda.
- Five directors elected: Geoffrey Dow, Eric Francois, Cheryl Xu, Stephen Toovey, Paul Field.
- Ratification of RBSM LLP as independent auditor for FY 2026 approved.

## SEC filing metadata
- accession: 0001213900-26-086136
- form_type: 8-K
- ticker: SXTP
- cik: 0001946563
- company_name: 60 DEGREES PHARMACEUTICALS, INC.
- filed_at: 2026-08-06T20:07:36+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1946563/000121390026086136/0001213900-26-086136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1946563/000121390026086136/ea0300977-8k_60degrees.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-086136
- JSON: https://secwatch.observer/filing/0001213900-26-086136.json
- Plain text: https://secwatch.observer/filing/0001213900-26-086136.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.